A5054174658- Cancer-related Molecular Pathways
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- 3D Printing in Biomedical Research
- Cancer Research and Treatments
- Pulmonary Hypertension Research and Treatments
- Ubiquitin and proteasome pathways
- Autophagy in Disease and Therapy
- Spinal Cord Injury Research
- Cancer Cells and Metastasis
- Liver physiology and pathology
- Microtubule and mitosis dynamics
- Nerve injury and regeneration
- Mathematical Biology Tumor Growth
- Tissue Engineering and Regenerative Medicine
- Hernia repair and management
- Nerve Injury and Rehabilitation
- Breast Lesions and Carcinomas
- Evolution and Genetic Dynamics
- Connective tissue disorders research
- Antenna Design and Analysis
- Multiple Myeloma Research and Treatments
- Inhalation and Respiratory Drug Delivery
- Microfluidic and Bio-sensing Technologies
- Intestinal and Peritoneal Adhesions
- Advanced Fiber Optic Sensors
Tianjin Medical University
2024
Second Hospital of Tianjin Medical University
2024
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
2023-2024
Zaozhuang Municipal Hospital
2024
University of Electronic Science and Technology of China
2016-2024
Huazhong University of Science and Technology
2023
Tongji Hospital
2023
East China University of Science and Technology
2016-2022
Drexel University
2022
Tsinghua University
2022
Abstract Blocking the oncoprotein murine double minute 2 (MDM2)–p53 protein–protein interaction has long been considered to offer a broad cancer therapeutic strategy, despite potential risks of selecting tumors harboring p53 mutations that escape MDM2 control. In this study, we report novel small-molecule inhibitor MDM2–p53 interaction, SAR405838 (MI-77301), advanced into phase I clinical trials. binds with Ki = 0.88 nmol/L and high specificity over other proteins. A cocrystal structure...
Hepatic stellate cells (HSCs), a major component of the tumor microenvironment in liver cancer, play important roles cancer progression as well drug resistance.
Alveolar epithelial cell (AEC) senescence-induced changes of lung mesenchymal cells are key to starting the progress pulmonary fibrosis. Follistatin-like 1 (FSTL1) plays a central regulatory role in complex process senescence and fibrosis by enhancing transforming growth factor-β1 (TGF-β1) signal pathway activity. Activation Smad4 Ras relies on SUMO-specific peptidase (SENP1)-mediated deSUMOylation during TGF-β signaling activation. We hypothesized that SENP1-mediated may be potential...
Lung cancer is the most common cause of cancer-related death. Although anti-angiogenesis therapy has been effective in treatment nonsmall cell lung (NSCLC), drug-resistance a challenge. Therefore, there need to develop new therapeutic strategies for NSCLC. Serine/threonine-protein kinase 24 (STK24), also known as MST3, belongs germinal center III subfamily, and biological function STK24 NSCLC tumorigenesis tumor angiogenesis still unclear. In this study, we demonstrated that was...
Multiple myeloma (MM) is the second most common hematologic malignancy. There are no standard therapeutic guidelines for extramedullary invasion (EM). We performed a retrospective integrated transcriptomic analysis based on GEO, TCGA, and Oncomine datasets with total of over 2,500 cases enrolled. GSVA was GSE24080. The external validation cohorts include GSE9782, GSE2658, MMRF-COMPASS, Oncomine. data MGUS to relapsed MM were acquired from GSE6477, GSE5900, EM GSE39683 GSE66291. Single-cell...
Idiopathic pulmonary fibrosis (IPF) is an age-related lung interstitial disease that occurs predominantly in people over 65 years of age and for which there a lack effective therapeutic agents. It has demonstrated mesenchymal stem cells (MSCs) including alveolar epithelial (AECs) can perform repair functions. However, MSCs lose their functions due to distinctive aging characteristics, eventually leading the progression IPF. Recent breakthroughs have revealed degree autophagic activity...
Cisplatin is a platinum-based chemotherapeutic drug widely used in the treatment of various cancers such as testicular, ovarian, lung, bladder, and cervical cancers. However, its use dosage range applied have been limited by severe side effects (e.g., nephrotoxicity ototoxicity) development resistance to cisplatin patients during treatment. Metal chelators shown promising potential overcoming these problems often associated with platinum drugs. Previously, new chelating agent, sodium...
Multi-threshold 2D discrete wavelet based on BayesShrink method is utilized to enhance the SNR of BOTDA. Then a 154.42 BOTDA experimentally demonstrated with 40ns pump pulses, and measurement uncertainty reduced from ±1.52MHz down ±1.03MHz.
Increasing lung diseases, mutating coronaviruses, and the development of new compounds urgently require biomimetic in vitro models for pathology, toxicology, pharmacology. The current construction strategies mainly include animal models, 2D cell culture, lung-on-a-chip, organoids. However, face difficulties reproducing vivo-like alveolar size vesicle-like structures, are unable to contain multiple types. In this study, a strategy constructing based on degradable hydrogel microspheres is...
In this letter, a novel compact wideband antenna with broadside and conical diversity patterns is presented for fifth-generation (5G)-NR applications. The capacitive loading implemented to enhance the port isolation size reduction (0.35 λ <sub xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</sub> × 0.29 0.047 ). With an extra slot mode introduced by coupled feeding scheme, wide impedance bandwidth obtained. A miniaturized broadband 180° hybrid...
Abstract The disruption of the MDM2‐p53 interaction has been regarded as an attractive strategy for anticancer drug discovery. Here, natural small‐molecule SCY45 was identified a potent inhibitor based on fluorescence polarization and molecular modeling. inhibited with IC 50 value 4.93±0.08 μ m . structural modeling results showed that not only had high similarity nutlin‐3a, well‐reported MDM2‐P53 inhibitor, but also bound to p53 binding pocket MDM2 mode similar nutlin‐3a. Moreover, reduced...
Abstract Activation of p53 by blocking the interaction MDM2-p53 using non-peptide small-molecule inhibitors is being pursued as a promising new cancer therapeutic strategy. Although genetic activation has been shown to achieve complete tumor eradication in mice, best reported date (Nutlins including RG7112 or first generation spiro-oxindoles such AT219) can only inhibit growth but fail significant regression animal models human cancer. In present study, we demonstrate, for time, that 2...
This study aimed to summarize the clinical manifestations and ultrasound characteristics of primary thyroid lymphoma (PTL) explore key aspects in process diagnosing PTL.
matrix metalloproteunase, MMP)降解基质胶(胞外基质)是肿瘤细胞进行侵袭的 关键步骤之一.细胞坏死因子(tumor necrosis factor-α, TNF-)能够诱导乳腺肿瘤细胞(MDA-MB-231)分泌 MMP9, 从而提高肿瘤发生 [
Abstract Drug resistance is recognized as being the major obstacle to be overcome during systemic chemotherapy of cancer. Tremendous amounts molecular mechanisms results in cell they develop. Resistance always arises after drug application. The rate at which occurs under mutation induced by affected kinetics. Yet, it isn’t clear how kinetic factors affect evolution resistance. Here, we developed a mathematical model describe growth resistant subpopulation along with effect different drugs...
<div>Abstract<p>Blocking the oncoprotein murine double minute 2 (MDM2)–p53 protein–protein interaction has long been considered to offer a broad cancer therapeutic strategy, despite potential risks of selecting tumors harboring p53 mutations that escape MDM2 control. In this study, we report novel small-molecule inhibitor MDM2–p53 interaction, SAR405838 (MI-77301), advanced into phase I clinical trials. binds with <i>K</i><sub>i</sub> = 0.88 nmol/L and...
<div>Abstract<p>Blocking the oncoprotein murine double minute 2 (MDM2)–p53 protein–protein interaction has long been considered to offer a broad cancer therapeutic strategy, despite potential risks of selecting tumors harboring p53 mutations that escape MDM2 control. In this study, we report novel small-molecule inhibitor MDM2–p53 interaction, SAR405838 (MI-77301), advanced into phase I clinical trials. binds with <i>K</i><sub>i</sub> = 0.88 nmol/L and...